A carregar...
Consistent improvement with eculizumab across muscle groups in myasthenia gravis
OBJECTIVE: To assess whether eculizumab, a terminal complement inhibitor, improves patient‐ and physician‐reported outcomes (evaluated using the myasthenia gravis activities of daily living profile and the quantitative myasthenia gravis scale, respectively) in patients with refractory anti‐acetylcho...
Na minha lista:
| Publicado no: | Ann Clin Transl Neurol |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7448154/ https://ncbi.nlm.nih.gov/pubmed/32700461 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/acn3.51121 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|